Valuation: GlucoTrack, Inc.

Market Cap 3.08M 2.69M 2.48M 2.29M 4.31M 297M 4.41M 29.68M 11.67M 145M 11.57M 11.31M 500M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -857K -749K -691K -637K -1.2M -82.57M -1.23M -8.26M -3.25M -40.44M -3.22M -3.15M -139M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.07%
Yield 2024 *
-
Yield 2025 -
1 day-1.60%
1 week+17.87%
Current month+54.23%
1 month+33.51%
3 months-38.42%
6 months-87.58%
Current year-87.29%
1 week 0.4
Extreme 0.4
0.63
1 month 0.3
Extreme 0.301
0.63
Current year 0.29
Extreme 0.2907
4.24
1 year 0.29
Extreme 0.2907
14.14
3 years 0.29
Extreme 0.2907
5,939.99
5 years 0.29
Extreme 0.2907
46,800.05
10 years 0.29
Extreme 0.2907
468,000.47
Manager TitleAgeSince
Chief Executive Officer 59 -
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 59 2024-08-26
Director/Board Member 56 2023-08-24
Chairman 63 2024-02-12
Date Insider Type Main position Quantity % Market Cap.
3/26/25 Free

Director

4,490 0.0431%
3/25/25 Others

Chief Executive Officer

42 0.0004%
3/25/25 Free

Director

8,747 0.0840%
Change 5-day change 1-year change 3-year change Capi.($)
-1.60%+17.87%-91.56%-99.98% 3.08M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average -0.11%+1.81%+48.47%+76.39% 24.36B
Weighted average by Cap. -0.05%-0.18%+79.44%+123.31%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.75M -18.22M -16.8M -31.66M -2.18B -32.36M -218M -85.67M -1.07B -84.86M -83M -3.67B -19.39M -16.94M -15.63M -14.41M -27.16M -1.87B -27.77M -187M -73.5M -914M -72.81M -71.21M -3.15B
Net Debt -5.35M -4.68M -4.31M -3.98M -7.5M -515M -7.66M -51.57M -20.28M -252M -20.09M -19.65M -869M -3.94M -3.44M -3.17M -2.93M -5.52M -379M -5.64M -37.95M -14.93M -186M -14.79M -14.46M -639M
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
26-07-17 US$0.4920 -1.60% 20,921,074
26-07-16 US$0.5000 -5.48% 26,424,019
26-07-15 US$0.5290 -0.02% 63,939,956
26-07-14 US$0.5291 +14.13% 39,545,723
26-07-13 US$0.4636 +11.07% 313,396
  1. Stock Market
  2. Stocks
  3. GCTK Stock